top of page
NEWS
A new biotech emerged to take forward the lead preclinical work developed by Frequency Therapeutics, a regenerative medicines company that...
Progentos is doing remarkable work, and its lead pipeline candidate has the potential to be the first restorative therapy and transform the treatment of MS
Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through “proof of concept” testing.
bottom of page